MYRIAD GENETICS, INC.
MYGN · NASDAQ
Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.
Market Data
Price
$5.12
+0.31 (+6.44%)
Market Cap$479M
P/E Ratio—
EPS$—
52W High$11.44
52W Low$3.76
Beta1.94
Data from Finnhub · Updated Mar 11, 2026